PRIA Logo™
119-s-3598119th CongressWALLET

Better Care for PFAS Patients Act of 2026

Sponsored By: Senator Shaheen, Jeanne [D-NH]

Introduced

Summary

Create regular, science-based clinical guidance on PFAS health effects. The bill would require the Agency for Toxic Substances and Disease Registry to hire the National Academies to assess PFAS measurable in human tissues and to craft clinical recommendations with community input and set timelines for reports and updates.

Show full summary
  • PFAS-exposed communities would be invited to take part and share experiences about exposure, testing, and clinical follow-up as part of the assessment.
  • Health care professionals and state and local public health authorities would receive clinical recommendations posted on the ATSDR website and disseminated to appropriate clinicians.
  • The assessing body would complete an initial report and recommendations within 2 years and the Director would update guidance at least every 5 years or sooner if science requires.
  • The ATSDR Director would have to enter the required agreement within 60 days of enactment and then issue up-to-date clinical guidance within 5 years of that agreement.

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

Analyzed Economic Effects

1 provisions identified: 1 benefits, 0 costs, 0 mixed.

Clinical PFAS guidance for exposed communities

This bill would require the ATSDR Director to hire the National Academies or a similar group within 60 days of enactment. That group would assess PFAS that can be measured in human tissues and make clinical recommendations. The group would finish an initial assessment and recommendations within 2 years of the agreement. ATSDR would issue, post, and share clinical guidance with State and local public health authorities and health care professionals within 5 years of the agreement. The guidance and the underlying assessment would be updated at least every 5 years, or sooner if the Director finds new science. The process would include outreach to PFAS-exposed communities and solicit their input on exposure, testing, and clinical follow-up.

Sponsors & CoSponsors

Sponsor

Shaheen, Jeanne [D-NH]

NH • D

Cosponsors

  • Sen. Collins, Susan M. [R-ME]

    ME • R

    Sponsored 1/8/2026

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation